Zero ad trackers.We never sell your data.Healthcare professional?Clinician Resources
Home/Rare Diseases/Paraganglioma

Rare Cancers

Paraganglioma Clinical Trials and Treatments

Also called extra-adrenal pheochromocytoma, neuroendocrine tumor, SDHA mutation

Paragangliomas are neuroendocrine tumors arising from chromaffin cells in extra-adrenal locations including the carotid bifurcation (carotid body tumor), jugular bulb, sympathetic chain, retroperitoneum, thorax, and bladder. Approximately 30-40% are hereditary, primarily caused by mutations in genes regulating succinate dehydrogenase (SDH complex) including SDHA, SDHB, SDHC, SDHD, and SDHAF2.

In plain words, paragangliomas are rare tumors that grow from certain nerve-related cells outside the adrenal glands. Some of these tumors release stress hormones, which can cause high blood pressure and a racing heartbeat along with sweating and headaches.

Get an email when new Paraganglioma trials open or the FDA decides. Get alerts

Paraganglioma

Where treatments stand, from ClinicalTrials.gov and FDA labels

FDA review0

No decision pending. FDA calendar

FDA-approved medicines1

Welireg

Paraganglioma has 1 FDA-approved medicine, 40 open or active clinical trials, and no pending FDA decision.

Labels checked October 21, 2026. Corticosteroids and immune globulins count once each.Download the data

Each date is the day a change was posted. Open an item to see where things stand now.

More about Paraganglioma

Other inherited causes include changes in the VHL, RET, NF1, TMEM127, MAX and FH genes. Paragangliomas in the head and neck usually make no catecholamines, according to the National Cancer Institute, while many in the chest, belly and pelvis do, presenting with hypertension, palpitations, panic attacks, and severe hyperadrenergic symptoms. Non-secreting tumors present with mass effects or are discovered incidentally on imaging. Critically, about 30-40% of paragangliomas have malignant potential with metastatic disease. Location, tumor size, rapid growth, and SDH mutation status (particularly SDHB) help predict malignant behavior.

Keep reading about Paraganglioma

Diagnosis combines biochemical testing (plasma metanephrines, 24-hour urinary catecholamines), imaging (CT, MRI, PET), and genetic testing. Histology shows nests of polygonal neuroendocrine cells separated by vascular fibrous septa.

What are the symptoms of Paraganglioma?

These are common symptoms of Paraganglioma, and how strong they are varies from person to person.

  • Hypertension and hypertensive episodes
  • Palpitations and tachycardia
  • Diaphoresis and flushing
  • Headaches and chest/abdominal pain
  • Metastatic disease in malignant forms
  • Variable hormone excess manifestations

Who gets Paraganglioma?

Can present at any age but hereditary forms often manifest in 30s-50s with peak in third and fourth decades. Sporadic tumors typically present later in adulthood. Affects males and females approximately equally in most series, with some male predominance reported.

Hereditary paraganglioma syndromes (PGL1-5) show autosomal dominant inheritance with variable penetrance. SDHB mutations, most commonly associated with malignancy, show higher penetrance and earlier presentation. Higher prevalence reported in Nordic, Eastern European, and certain other populations.

Next steps: find trials you might fitsee approved treatmentsget help payingget alerts

Which medicines are FDA-approved for Paraganglioma?

There is currently 1 FDA-approved medication for Paraganglioma.

belzutifan
Merck
Search

Source: openFDA drug labeling data. This list may not include all treatments. Always consult your doctor.

How to get help paying for Paraganglioma treatment

Charity funds and drugmaker programs for Paraganglioma, checked at the source.

Which insurance do you have? Pick one to see what fits. Tap it again to clear.
Your insurance
Charity funds

No charity fund for this condition is open right now. Funds reopen when they receive new donations; the foundations let you sign up to be told when one opens.

Status as each foundation showed it on November 9, 2026.
Drugmaker programs
Open a medicine for who qualifies, by insurance type.

Every program and fund for Paraganglioma, by insurance →

Side effects people have reported to the FDA

Side effects people have reported to the FDA

Real-world side effect reports from the FDA Adverse Event Reporting System (FAERS). Includes both FDA-approved drugs and investigational therapies from active clinical trials. Click any drug to see what patients reported.

Loading side effect data...

Diagnosis and genetic testing

Genetic testing for Paraganglioma

Genetic testing can confirm a diagnosis, guide treatment decisions, and identify family members who may be at risk.

Finding labs...

Trusted Paraganglioma resources

Reputable organizations and medical references for learning more about Paraganglioma, including disease registries, foundation resources, and clinical guidelines.

Active clinical trials for Paraganglioma

Use this Paraganglioma clinical trial finder to see the 19 studies recruiting patients and 6 not yet recruiting in the United States and worldwide, with eligibility criteria in plain English. Of these, 19 test a treatment and 6 are observational studies or registries; each card says which. Every trial comes from ClinicalTrials.gov.

Jump to the trial list, the site map or the pipeline timeline.

Note: Trial recruitment statuses on ClinicalTrials.gov may not immediately reflect recent FDA decisions, sponsor announcements, or enrollment changes. Always confirm a trial's current status directly with the study coordinator before making plans.

40 active trials worldwide
Filter:
Sort:
RecruitingTreatment trialPhase 2Recently updatedNCT04924075

Belzutifan/MK-6482 for the Treatment of Advanced Pheochromocytoma/Paraganglioma (PPGL), Pancreatic Neuroendocrine Tumor (pNET), Von Hippel-Lindau (VHL) Disease-Associated Tumors, Advanced Gastrointestinal Stromal Tumor (wt GIST), or Solid Tumors With HIF-2α Related Genetic Alterations (MK-6482-015)

Intervention: Belzutifan

Sponsor: Merck Sharp & Dohme LLC

This is a study to evaluate the efficacy and safety of belzutifan monotherapy in participants with advanced pheochromocytoma/paraganglioma (PPGL), pancreatic neuroendocrine tumor (pNET), von Hippel-Lindau (VHL) disease-associated tumors, advanced wt (wild-type) gastrointestinal s...

Ages 12 Years+
Started Aug 2021Updated 5 days agoEst. Nov 2032 (~6 years)
RecruitingTreatment trialPhase 1Recently updatedNCT06041516

A First-in-Human Phase I Trial With Antibody Drug Conjugate ADCT-701 in Neuroendocrine Tumors, Carcinomas and Malignant Peripheral Nerve Sheath Tumors

Intervention: ADCT-701

Sponsor: National Cancer Institute (NCI)

Background:

Neuroendocrine neoplasms (NENs) are rare cancers in the gastrointestinal tract, pancreas, lungs, adrenal glands, and other areas of the body. Many of these cancers have a high risk of relapse and a low chance of survival. Better treatments are needed.

Objective:

Ages 18 Years to 120 Years1 location
Started Jun 2024Updated 1 week agoEst. Oct 2027 (~11 months)
RecruitingPatient registry covering many conditionsRecently updatedNCT07920198

Adrenal Diseases in the Population of Modena: A Clinical-Epidemiological Database of Patients Referred to the Adrenal Disorders Outpatient Clinic of the Clinical Unit of Endocrinology at the Modena University Hospital (AOU Modena)

Sponsor: Azienda Ospedaliero-Universitaria di Modena

Primary Objective: The primary objective of the study is to characterize subjects affected by adrenal disease by collecting medical history data at diagnosis, clinical, bio-humoral, and radiological data, as well as information regarding the therapeutic approach, in terms of both...

Ages 18 Years+1 location
Started Jul 2026Updated 1 week agoEst. Feb 2030 (~3y 2m)
RecruitingObservational study, no treatment givenRecently updatedNCT03160274

Genetic Analysis of Pheochromocytomas, Paragangliomas and Associated Conditions

Intervention: Genetic screening

Sponsor: The University of Texas Health Science Center at San Antonio

Pheochromocytomas and paragangliomas are neural crest-derived tumors of the nervous system that are often inherited and genetically heterogeneous. Genetic screening is recommended for patients and their relatives, and can guide clinical decisions. However, a mutation is not found in all cases.

Ages not specified1 location
Started Oct 2005Updated 1 week agoEst. Dec 2030 (~4y 1m)
RecruitingTreatment trialPhase 4Recently updatedNCT04081701

68-Ga DOTATATE PET/MRI in the Diagnosis and Management of Somatostatin Receptor Positive CNS Tumors.

Intervention: Ga68-DOTATATE-PET/MRI

Sponsor: Weill Medical College of Cornell University · Novartis Pharmaceuticals

The study population consists of patients who undergo resection for somatostatin receptor-positive (SSTR-positive) CNS tumors, focusing on meningioma, and including esthesioneuroblastoma, hemangioblastoma, medulloblastoma, paraganglioma, pituitary adenoma, and SSTR-positive syste...

Ages 18 Years to 100 Years1 location
Started Sep 2019Updated 2 weeks agoEst. Dec 2038 (~12y 1m)
Find Paraganglioma trials near you, ranked by distance →
Active trial locations35 cities in the US
A study site. Select it to see its trials and get directions. Several sites close together. Select the number to zoom in.
+27 more

Trial Pipeline

Jan 2021 to Nov 2031
2021
2023
2025
2027
2029
2031
now
Early Phase 1
Phase 1
Phase 2
Phase 4
Observational
Observational
RecruitingNot yet recruitingDelayed startTodayHover a bar for trial details

Read more about Paraganglioma trials

Need help understanding these trials?
Answers with sources, in plain English
Start withor ask
Run a Paraganglioma foundation or patient group?
You can put this live trial list on your own website. It updates itself, and it's free.
Get the embed code →

Data from ClinicalTrials.gov, U.S. National Library of Medicine.
Always talk to your doctor before considering a clinical trial.

Paraganglioma patient communities

Facebook groups, Reddit communities and YouTube channels where Paraganglioma patients, caregivers and advocacy groups talk.

Companies developing Paraganglioma treatments

Drugmakers that list Paraganglioma in their rare disease portfolio, 11 in all.

Questions people ask about Paraganglioma